Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 783 of 1,261
  1. US 8883818

    Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

    TAKEDA GMBH · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  2. US 8883781

    Thienopyrimidines useful as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  3. US 8883766

    Ion channel modulators and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  4. US 8883729

    Nanolipoprotein particles and related compositions, methods and systems

    The Board of Regents of the University of Texas System · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  5. US 8883448

    Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  6. US 8883500

    Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy

    Northwestern University · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  7. US 8883214

    Implantable delivery vehicle for ocular delivery of muscarinic antagonists

    The Regents of the University of California · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  8. US 8883438

    Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

    Agios Pharmaceuticals, Inc. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  9. US 8883211

    Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds

    Serina Therapeutics, Inc. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  10. US 8883202

    Lipid compositions

    Tekmira Pharmaceuticals Corporation · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  11. US 8883189

    Intraocular encapsulation of oxygenic bacteria

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  12. US 8883185

    Hydrogel implants with varying degrees of crosslinking

    Covidien LP · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  13. US 8883155

    Methods for treating hematopoietic malignancies

    The Regents of the University of California · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  14. US 8883154

    Antibody-mediated modulation of allergy

    The Board of Regents of the University of Texas System · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  15. US 8883174

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    The Board of Regents of the University of Texas System · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  16. US 8883161

    Fusion polypeptide against EB virus-induced tumor and colicin Ia mutant

    PROTEIN DESIGN LAB, LTD. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted
  17. US 8875970

    Structure containing wound treatment material

    Covidien LP · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  18. US 8877917

    Glycoconjugates of RNA interference agents

    Alnylam Pharmaceuticals, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  19. US 8877796

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  20. US 8877765

    Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  21. US 8877797

    Methods for treating Parkinson's disease using pro-neurogenic compounds

    The Board of Regents of the University of Texas System · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  22. US 8877914

    Compositions comprising nucleic acids encoding HIV-1 reverse transcriptase CTL epitopes

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  23. US 8877726

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  24. US 8877721

    Small activating RNA molecules and methods of use

    The Regents of the University of California · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.